ABOS insider transaction filings
Acumen Pharmaceuticals, Inc. — 45 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-06-17. Screen ABOS transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-17 | 4 | Porter Derrell — Director | Option exercise (M): 6,460 @ $1.07 · Sale (S): 6,460 @ $2.35 · Sale (S): 12,800 @ $2.33 · Option exercise (M): 13,040 @ $1.07 · Sale (S): 13,040 @ $2.33 · Option exercise (M): 6,460 (derivative) @ $0 · +1 more | EDGAR |
| 2026-06-10 | 4 | Fountain Nathan B — Director | Sale (S): 6,400 @ $2.23 | EDGAR |
| 2026-06-05 | 4 | Fountain Nathan B — Director | Grant/award (A): 35,500 @ $0 · Grant/award (A): 53,250 (derivative) @ $0 | EDGAR |
| 2026-06-05 | 4 | Stalfort John A III — Director | Grant/award (A): 35,500 @ $0 · Grant/award (A): 53,250 (derivative) @ $0 | EDGAR |
| 2026-06-05 | 4 | Porter Derrell — Director | Grant/award (A): 35,500 @ $0 · Grant/award (A): 53,250 (derivative) @ $0 | EDGAR |
| 2026-06-05 | 4 | Ives Jeffrey L. — Director | Grant/award (A): 35,500 @ $0 · Grant/award (A): 53,250 (derivative) @ $0 | EDGAR |
| 2026-06-05 | 4 | Golumbeski George — Director | Grant/award (A): 35,500 @ $0 · Grant/award (A): 53,250 (derivative) @ $0 | EDGAR |
| 2026-06-05 | 4 | Stoppel Laura — Director | Grant/award (A): 35,500 @ $0 · Grant/award (A): 53,250 (derivative) @ $0 | EDGAR |
| 2026-06-05 | 4 | Drapkin Kimberlee C — Director | Grant/award (A): 35,500 @ $0 · Grant/award (A): 53,250 (derivative) @ $0 | EDGAR |
| 2026-06-05 | 4 | RA CAPITAL MANAGEMENT, L.P. — Director, 10% owner RA Capital Healthcare Fund LP — Director, 10% owner RA Capital Nexus Fund II, L.P. — Director Kolchinsky Peter — Director, 10% owner Shah Rajeev M. — Director, 10% owner | Grant/award (A): 35,500 @ $0 · Grant/award (A): 53,250 (derivative) @ $0 | EDGAR |
| 2026-03-18 | 4 | RA CAPITAL MANAGEMENT, L.P. — Director, 10% owner RA Capital Healthcare Fund LP — Director, 10% owner RA Capital Nexus Fund II, L.P. — Director Kolchinsky Peter — Director, 10% owner Shah Rajeev M. — Director, 10% owner | Grant/award (A): 6,060,606 @ $3.30 | EDGAR |
| 2026-03-10 | 4 | Meisner Derek M — Chief Legal Officer & Corp Sec | Option exercise (M): 2,090 @ $1.85 · Sale (S): 2,090 @ $3.26 · Option exercise (M): 2,090 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | Meisner Derek M — Chief Legal Officer & Corp Sec | Option exercise (M): 9,406 @ $1.85 · Sale (S): 9,406 @ $3.01 · Option exercise (M): 9,406 (derivative) @ $0 | EDGAR |
| 2026-01-28 | 4 | Meisner Derek M — Chief Legal Officer & Corp Sec | Option exercise (M): 15,085 @ $1.85 · Sale (S): 15,085 @ $3.00 · Option exercise (M): 2,671 @ $1.85 · Sale (S): 2,671 @ $3.00 · Option exercise (M): 15,085 (derivative) @ $0 · Option exercise (M): 2,671 (derivative) @ $0 | EDGAR |
| 2026-01-23 | 4 | Meisner Derek M — Chief Legal Officer & Corp Sec | Sale (S): 2,247 @ $1.81 · Sale (S): 1,054 @ $1.84 · Sale (S): 5,633 @ $1.90 | EDGAR |
| 2026-01-23 | 4 | Siemers Eric — Chief Medical Officer | Sale (S): 2,331 @ $1.80 · Sale (S): 895 @ $1.82 | EDGAR |
| 2026-01-23 | 4 | Zuga Matt — CFO & Chief Business Officer | Sale (S): 2,473 @ $1.81 · Sale (S): 1,687 @ $1.86 | EDGAR |
| 2026-01-23 | 4 | OConnell Daniel Joseph — Chief Executive Officer, Director | Sale (S): 9,346 @ $1.81 · Sale (S): 2,689 @ $1.88 | EDGAR |
| 2026-01-23 | 4 | Barton Russell — Chief Operating Officer | Sale (S): 2,315 @ $1.81 · Sale (S): 462 @ $1.84 | EDGAR |
| 2026-01-21 | 4 | OConnell Daniel Joseph — Chief Executive Officer, Director | Grant/award (A): 299,800 @ $0 · Grant/award (A): 450,000 (derivative) @ $0 | EDGAR |
| 2026-01-21 | 4 | Zuga Matt — CFO & Chief Business Officer | Grant/award (A): 99,133 @ $0 · Grant/award (A): 148,700 (derivative) @ $0 | EDGAR |
| 2026-01-21 | 4 | Meisner Derek M — Chief Legal Officer & Corp Sec | Grant/award (A): 99,133 @ $0 · Grant/award (A): 148,700 (derivative) @ $0 | EDGAR |
| 2026-01-21 | 4 | Siemers Eric — Chief Medical Officer | Grant/award (A): 99,133 @ $0 · Grant/award (A): 148,700 (derivative) @ $0 | EDGAR |
| 2026-01-21 | 4 | Barton Russell — Chief Operating Officer | Grant/award (A): 84,600 @ $0 · Grant/award (A): 126,900 (derivative) @ $0 | EDGAR |
| 2026-01-21 | 4 | Schacterle Amy — Chief Regulatory Officer | Grant/award (A): 84,600 @ $0 · Grant/award (A): 126,900 (derivative) @ $0 | EDGAR |
| 2026-01-21 | 4 | Doherty James J. — President and CDO | Grant/award (A): 166,867 @ $0 · Grant/award (A): 250,300 (derivative) @ $0 | EDGAR |
| 2026-01-12 | 4 | Zuga Matt — CFO & Chief Business Officer | Sale (S): 6,888 @ $1.82 | EDGAR |
| 2026-01-12 | 4 | Barton Russell — Chief Operating Officer | Sale (S): 3,530 @ $1.86 | EDGAR |
| 2026-01-12 | 4 | Meisner Derek M — Chief Legal Officer & Corp Sec | Sale (S): 6,819 @ $1.82 · Sale (S): 30,092 @ $1.82 · Sale (S): 5,200 @ $1.76 · Sale (S): 8,548 @ $1.71 | EDGAR |
| 2026-01-12 | 4 | OConnell Daniel Joseph — Chief Executive Officer, Director | Sale (S): 8,143 @ $1.82 · Sale (S): 12,941 @ $1.76 · Sale (S): 5,388 @ $1.73 | EDGAR |
| 2026-01-09 | 4 | Doherty James J. — President and CDO | Sale (S): 1,700 @ $1.99 · Sale (S): 6,467 @ $1.82 | EDGAR |
| 2026-01-09 | 4 | Schacterle Amy — Chief Regulatory Officer | Sale (S): 1,097 @ $1.98 | EDGAR |
| 2026-01-07 | 4 | Zuga Matt — CFO & Chief Business Officer | Sale (S): 4,000 @ $1.96 · Sale (S): 5,100 @ $1.97 · Sale (S): 4,105 @ $2.00 · Sale (S): 1,700 @ $1.99 | EDGAR |
| 2026-01-07 | 4 | Siemers Eric — Chief Medical Officer | Sale (S): 4,000 @ $1.96 · Sale (S): 6,834 @ $1.97 | EDGAR |
| 2026-01-07 | 4 | OConnell Daniel Joseph — Chief Executive Officer, Director | Sale (S): 4,649 @ $1.97 · Sale (S): 5,102 @ $1.97 · Sale (S): 37,755 @ $1.99 | EDGAR |
| 2026-01-07 | 4 | Meisner Derek M — Chief Legal Officer & Corp Sec | Sale (S): 4,000 @ $1.96 · Sale (S): 7,097 @ $1.97 · Sale (S): 3,801 @ $1.97 · Sale (S): 1,700 @ $1.99 · Sale (S): 10,070 @ $1.99 | EDGAR |
| 2026-01-07 | 4 | Barton Russell — Chief Operating Officer | Sale (S): 4,000 @ $1.96 · Sale (S): 3,618 @ $1.97 · Sale (S): 1,700 @ $1.99 | EDGAR |
| 2025-11-10 | 4 | Golumbeski George — Director | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2025-06-05 | 4 | Stoppel Laura — Director | Grant/award (A): 12,800 @ $0 · Grant/award (A): 19,500 (derivative) @ $0 | EDGAR |
| 2025-06-05 | 4 | Stalfort John A III — Director | Grant/award (A): 12,800 @ $0 · Grant/award (A): 19,500 (derivative) @ $0 | EDGAR |
| 2025-06-05 | 4 | Fountain Nathan B — Director | Grant/award (A): 12,800 @ $0 · Grant/award (A): 19,500 (derivative) @ $0 | EDGAR |
| 2025-06-05 | 4 | Ives Jeffrey L. — Director | Grant/award (A): 12,800 @ $0 · Grant/award (A): 19,500 (derivative) @ $0 | EDGAR |
| 2025-06-05 | 4 | Porter Derrell — Director | Grant/award (A): 12,800 @ $0 · Grant/award (A): 19,500 (derivative) @ $0 | EDGAR |
| 2025-06-05 | 4 | Drapkin Kimberlee C — Director | Grant/award (A): 12,800 @ $0 · Grant/award (A): 19,500 (derivative) @ $0 | EDGAR |
| 2025-06-05 | 4 | RA CAPITAL MANAGEMENT, L.P. — Director, 10% owner RA Capital Healthcare Fund LP — Director, 10% owner RA Capital Nexus Fund II, L.P. — Director Kolchinsky Peter — Director, 10% owner Shah Rajeev M. — Director, 10% owner | Grant/award (A): 12,800 @ $0 · Grant/award (A): 19,500 (derivative) @ $0 | EDGAR |
Recent 8-K events — Acumen Pharmaceuticals, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-12 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-16 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-03 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-12 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-26 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-16 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-12 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-12 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-10 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-08-12 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=ABOS returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →